Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Factors Influencing the Human Gut Microbiome Profile in Multi-ethnic Groups of the Singapore Community (FAMES)
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2016-09-08
- Lead Sponsor
- Changi General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT02893709
- Locations
- 🇸🇬
Changi General Hospital, Singapore, Singapore
Effect of Proton Pump Inhibitors on Gut Microbiota and Systemic Inflammation in Older Adults
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2017-01-20
- Target Recruit Count
- 25
- Registration Number
- NCT02844621
- Locations
- 🇺🇸
First Outpatient Research Unit, Medical Arts and Research Center, San Antonio, Texas, United States
A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 32
- Registration Number
- NCT02790840
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02783040
- Locations
- 🇩🇪
1346.22.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT02772601
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Berlin, Germany
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Takeda
- Registration Number
- NCT02760615
- Locations
- 🇺🇸
WCCT, Cypress, California, United States
🇺🇸QPS MRA, Miami, Florida, United States
Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
- Conditions
- Interventions
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT02740712
- Locations
- 🇵🇱
BioVirtus Research Site, Kajetany, Mokra 7, Poland
🇵🇱Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin, Poland
🇵🇱Med Polonia, Poznan, Poland
Pharmacodynamics and Safety of CDFR0209
- Conditions
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT02710994
- Locations
- 🇰🇷
Ajou University Medical Center, Suwon, Gyeonggi, Korea, Republic of
Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 157
- Registration Number
- NCT02685150
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02684799
- Locations
- 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.